Cargando…
A Case Study of Chimeric Antigen Receptor T Cell Function: Donor Therapeutic Differences in Activity and Modulation with Verteporfin
SIMPLE SUMMARY: The loss of tumor antigens prevents the immune system from recognizing and destroying cancer cells. Immune cells can remove these antigens and express them on their surface. Other immune cells becoming confused, kill the anti-tumor immune cells. By blocking this process using a drug...
Autores principales: | Liang, Jiyong, Fang, Dexing, Gumin, Joy, Najem, Hinda, Sooreshjani, Moloud, Song, Renduo, Sabbagh, Aria, Kong, Ling-Yuan, Duffy, Joseph, Balyasnikova, Irina V., Pollack, Seth M., Puduvalli, Vinay K., Heimberger, Amy B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953964/ https://www.ncbi.nlm.nih.gov/pubmed/36831427 http://dx.doi.org/10.3390/cancers15041085 |
Ejemplares similares
-
The Use of Targeted Cytokines as Cancer Therapeutics in Glioblastoma
por: Sooreshjani, Moloud, et al.
Publicado: (2023) -
Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system
por: Wei, Jun, et al.
Publicado: (2022) -
Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy
por: Najem, Hinda, et al.
Publicado: (2021) -
LMD-20. Immune Suppressive Macrophages and Signal Transducer and Activator of Transcription 3 (STAT3) Expression are common in Melanoma Leptomeningeal Disease
por: Najem, Hinda, et al.
Publicado: (2021) -
Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma
por: Boudreau, C. Elizabeth, et al.
Publicado: (2021)